Real-time Estimate
Cboe BZX
12:33:20 2024-06-03 pm EDT
|
5-day change
|
1st Jan Change
|
3.345
USD
|
-1.04%
|
|
+6.39%
|
+9.88%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
935.7
|
1,388
|
2,029
|
306.1
|
213
|
238.5
|
-
|
-
|
Enterprise Value (EV)
1 |
935.7
|
1,388
|
2,029
|
306.1
|
213
|
238.5
|
238.5
|
238.5
|
P/E ratio
|
-76.1
x
|
-54.6
x
|
-94.8
x
|
-9.14
x
|
-2.72
x
|
-5.07
x
|
-5
x
|
-12.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
13.7
x
|
20.1
x
|
19.4
x
|
2.21
x
|
3.04
x
|
3.67
x
|
3.72
x
|
2.74
x
|
EV / Revenue
|
13.7
x
|
20.1
x
|
19.4
x
|
2.21
x
|
3.04
x
|
3.67
x
|
3.72
x
|
2.74
x
|
EV / EBITDA
|
-232
x
|
-97.4
x
|
-254
x
|
-10.4
x
|
-3.4
x
|
-6.11
x
|
-5.22
x
|
-
|
EV / FCF
|
-57.4
x
|
-60.8
x
|
-56.8
x
|
-133
x
|
-3.73
x
|
-3.98
x
|
-5.78
x
|
-13.9
x
|
FCF Yield
|
-1.74%
|
-1.64%
|
-1.76%
|
-0.75%
|
-26.8%
|
-25.1%
|
-17.3%
|
-7.2%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
58,518
|
63,568
|
64,875
|
65,687
|
69,830
|
70,558
|
-
|
-
|
Reference price
2 |
15.99
|
21.83
|
31.27
|
4.660
|
3.050
|
3.380
|
3.380
|
3.380
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
68.46
|
69.06
|
104.8
|
138.6
|
70.14
|
64.96
|
64.05
|
87.03
|
EBITDA
1 |
-4.036
|
-14.24
|
-7.991
|
-29.48
|
-62.55
|
-39.05
|
-45.71
|
-
|
EBIT
1 |
-12.55
|
-23.92
|
-22.7
|
-34.88
|
-68.07
|
-46.62
|
-45.45
|
-16.29
|
Operating Margin
|
-18.33%
|
-34.64%
|
-21.67%
|
-25.17%
|
-97.04%
|
-71.76%
|
-70.95%
|
-18.71%
|
Earnings before Tax (EBT)
1 |
-11.92
|
-23.67
|
-21.09
|
-33.32
|
-76.17
|
-47.98
|
-47.2
|
-22.2
|
Net income
1 |
-11.94
|
-24.01
|
-21.28
|
-33.59
|
-76.24
|
-47.05
|
-47.88
|
-22.2
|
Net margin
|
-17.43%
|
-34.77%
|
-20.31%
|
-24.24%
|
-108.69%
|
-72.43%
|
-74.75%
|
-25.51%
|
EPS
2 |
-0.2100
|
-0.4000
|
-0.3300
|
-0.5100
|
-1.120
|
-0.6662
|
-0.6757
|
-0.2800
|
Free Cash Flow
1 |
-16.29
|
-22.82
|
-35.69
|
-2.294
|
-57.06
|
-59.86
|
-41.27
|
-17.16
|
FCF margin
|
-23.8%
|
-33.04%
|
-34.07%
|
-1.66%
|
-81.34%
|
-92.15%
|
-64.43%
|
-19.72%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
24.5
|
35.34
|
38.41
|
34.47
|
30.38
|
12.98
|
21.32
|
9.277
|
26.56
|
17.07
|
8.275
|
15.49
|
24.86
|
13
|
13.78
|
EBITDA
1 |
-6.369
|
-3.333
|
1.963
|
-4.7
|
-8.879
|
-19.39
|
-8.358
|
-27.29
|
1.498
|
-
|
-16.04
|
-11.54
|
-1.198
|
-16.8
|
-16.61
|
EBIT
1 |
-10.38
|
-8.386
|
-2.609
|
-10.64
|
-13.25
|
-23.66
|
-12.55
|
-32.06
|
0.282
|
-11.89
|
-17.78
|
-12.64
|
-4.014
|
-12.01
|
-11.65
|
Operating Margin
|
-42.39%
|
-23.73%
|
-6.79%
|
-30.86%
|
-43.62%
|
-182.29%
|
-58.88%
|
-345.59%
|
1.06%
|
-69.63%
|
-214.82%
|
-81.56%
|
-16.15%
|
-92.34%
|
-84.56%
|
Earnings before Tax (EBT)
1 |
-10.12
|
-8.347
|
-2.532
|
-9.984
|
-12.45
|
-22.6
|
-11.51
|
-34.9
|
-7.157
|
-11.5
|
-18
|
-13.11
|
-5.062
|
-12.12
|
-11.95
|
Net income
1 |
-10.19
|
-8.356
|
-2.64
|
-9.992
|
-12.6
|
-22.62
|
-11.52
|
-34.91
|
-7.192
|
-11.5
|
-18.02
|
-12.86
|
-4.237
|
-12.14
|
-11.97
|
Net margin
|
-41.59%
|
-23.64%
|
-6.87%
|
-28.99%
|
-41.5%
|
-174.22%
|
-54.04%
|
-376.29%
|
-27.08%
|
-67.39%
|
-217.78%
|
-82.99%
|
-17.05%
|
-93.33%
|
-86.87%
|
EPS
2 |
-0.1600
|
-0.1300
|
-0.0400
|
-0.1500
|
-0.1900
|
-0.3400
|
-0.1700
|
-0.5000
|
-0.1000
|
-0.1600
|
-0.2600
|
-0.1843
|
-0.0514
|
-0.1720
|
-0.1720
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/5/22
|
8/4/22
|
11/3/22
|
2/23/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/28/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-16.3
|
-22.8
|
-35.7
|
-2.29
|
-57.1
|
-59.9
|
-41.3
|
-17.2
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-0.2800
|
-0.1000
|
0.1700
|
-0.7700
|
-0.5100
|
-
|
-
|
Capex
1 |
3.73
|
3.75
|
13.8
|
8.31
|
4.42
|
10
|
2.75
|
8.28
|
Capex / Sales
|
5.45%
|
5.43%
|
13.17%
|
5.99%
|
6.3%
|
15.39%
|
4.29%
|
9.52%
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
3.38
USD Average target price
7.125
USD Spread / Average Target +110.80% Consensus |
1st Jan change
|
Capi.
|
---|
| +10.82% | 238M | | +43.36% | 54.63B | | -5.31% | 39.92B | | +37.40% | 38.82B | | +14.75% | 26.86B | | -12.56% | 26.22B | | -22.45% | 18.78B | | +25.12% | 12.21B | | +0.04% | 12.16B | | +26.04% | 11.94B |
Other Biotechnology & Medical Research
|